公开(公告)号：US11304966B2

公开(公告)日：2022-04-19

申请号：US16956511

申请日：2018-12-19

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).

公开(公告)号：US11224605B2

公开(公告)日：2022-01-18

申请号：US16303131

申请日：2017-05-19

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61P1/00 ,  A61P25/00

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for treating serotonin and/or tryptophan dysregulation.

公开(公告)号：US11173171B2

公开(公告)日：2021-11-16

申请号：US16820126

申请日：2020-03-16

Applicant: Glycom A/S

Inventor： Elise Champion ,  Bruce McConnell ,  Gyula Dekany

IPC: A61K31/702 ,  C07H3/06 ,  C12P19/14 ,  C12P19/26 ,  C07H1/00 ,  C12P19/00 ,  C07H5/06 ,  C12P19/18 ,  A61P31/04 ,  A61P31/12 ,  A61K31/7016

Abstract: A mixture of human milk oligosaccharides that consists essentially of 3′-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-0-fucosyl-3′-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3′-O-sialyllactose and component A with an α2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.

公开(公告)号：US20210252028A1

公开(公告)日：2021-08-19

申请号：US17114850

申请日：2020-12-08

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K45/06 ,  A61P31/00 ,  A61P3/10 ,  A61P29/00 ,  A61K35/20

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

公开(公告)号：US20210000848A1

公开(公告)日：2021-01-07

申请号：US17001118

申请日：2020-08-24

Applicant: GLYCOM A/S

Inventor： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC: A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

Abstract: A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

公开(公告)号：US10829508B2

公开(公告)日：2020-11-10

申请号：US16063465

申请日：2016-12-19

Applicant: GLYCOM A/S

Inventor： Manos Papadakis ,  Margit Pedersen ,  Katrine Bych

IPC: C07H3/06 ,  C12P19/18 ,  C12N9/10 ,  C07H1/00 ,  C07H3/02 ,  C12N15/70

Abstract: The invention relates to a microbial production of recombinant oligosaccharides, particularly of human milk oligosaccharides (HMOs), using a genetically modified microorganism, particularly E. coli, in antibiotic-free cultivating medium.

公开(公告)号：US10828313B2

公开(公告)日：2020-11-10

申请号：US15104794

申请日：2015-12-08

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

公开(公告)号：US10471084B2

公开(公告)日：2019-11-12

申请号：US15555936

申请日：2016-03-04

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/7048 ,  A61K31/702 ,  A61K9/20 ,  A23L33/125

Abstract: A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2′-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.

公开(公告)号：US10428318B2

公开(公告)日：2019-10-01

申请号：US15579843

申请日：2016-06-09

Applicant: Glycom A/S

Inventor： Andreas Vogel ,  Ramona Schmiedel ,  Elise Champion ,  Gyula Dekany

IPC: C12N9/10 ,  C12P21/00 ,  C07H3/06 ,  C12P19/18 ,  C12P19/04

Abstract: The invention provides engineered enzymes of transsialidase and/or sialyl transferase activity that have increased regioselectivity and/or increased thermostability.

公开(公告)号：US09896470B2

公开(公告)日：2018-02-20

申请号：US14407256

申请日：2013-06-14

Applicant: Glycom A/S

Inventor： Andreas Schroven ,  Gyula Dekany ,  Peter Erdmann ,  Andrea Schwarz

IPC: C07H1/06 ,  C07H3/06 ,  A61K31/702 ,  A23L29/30 ,  A23L33/00 ,  A23L33/10

CPC classification number: C07H1/06 ,  A23L5/00 ,  A23L29/30 ,  A23L33/10 ,  A23L33/125 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/00 ,  A61K31/702 ,  C07H3/06 ,  A23V2200/30 ,  A23V2200/3204 ,  A23V2250/28

Abstract: The present application discloses a method for enhancing the stability of a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend when stored for extended periods at temperatures above 25° C. by spray-drying an aqueous solution of the HMO or HMO precursor to remove at least 90% of the water and providing a HMO or a HMO precursor or a HMO blend with a specific glass transition temperature. Also disclosed is a method for removing organic solvent residues from a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend by spray drying. Also disclosed is a method of enhancing the bioavailability of a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend by spray drying.